α-(2,4-Dichlorophenyl)-1H-imidazole-1-ethanol

We are α-(2,4-Dichlorophenyl)-1H-imidazole-1-ethanol CAS:24155-42-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:α-(2,4-Dichlorophenyl)-1H-imidazole-1-ethanol
CAS.NO:24155-42-8
Synonyms:α-(2,4-Dichlorophenyl)-1H-imidazole-1-ethanol
1-(2,4-Dichlorophenyl)-2-(1-imidazolyl)ethanol
1-[2-(2,4-Dichlorophenyl)-2-hydroxyethyl]imidazole
1-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-yl)ethanol
1-(2-(2,4-dichlorophenyl)-2-hydroxyethyl)-1H-imidazole
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 468.5±45.0 °C at 760 mmHg
Melting Point 134-138 °C
Molecular Formula C11H10Cl2N2O
Molecular Weight 257.116
Flash Point 237.1±28.7 °C
 
Specification:
Appearance:Light brown to white crystalline powder
Assay(Titration):98.5-101.5%
Assay(HPLC):≥99.0%
Melting Point:134-138°C
Single impurity:≤0.14%
Total impurities:≤1.0%
Loss on drying:≤0.2%
Sulfated ash:≤0.1%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Miconazole Nitrate(CAS:228321-87-7).

α-(2,4-Dichlorophenyl)-1H-imidazole-1-ethanol


Related News: This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine.Isocianato de 4-cianofenilo CAS:40465-45-0 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.5-bromo-2-cloropiridina CAS:53939-30-3 As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.5-Cyanophthalide As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.Inceptua Medicines Access is a business unit of the Inceptua Group. It offers full access solutions for the design, implementation and delivery of Pre-approval and Medicines Access Programs on behalf of biopharmaceutical companies.

Related Products
Product Name
2′-Deoxyadenosine-5′-monophosphate disodium salt View Details
3-Cyanobenzylchloride View Details
Methyl 3-amino-2-fluorobenzoate View Details
(3,3-diphenyloxolan-2-ylidene)-dimethylazanium,bromide manufacturer 3-(2-methoxy-5-methylphenyl)-3-phenylpropan-1-ol manufacturer METHYL 2,4-DIFLUOROBENZOATE manufacturer 1,10-Decanediol manufacturer 1,3-difluoro-5-(trifluoromethyl)benzene manufacturer